Advanced Cancer clinical trials in Arizona

CBI-1214 for advanced colorectal cancer

This trial tests a new drug called CBI-1214, which is designed to help your immune system attack cancer cells. It is for people with advanced colorectal cancer that has not responded to other treatments.

AI matches your cancer tests to possible treatment trials

This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.

RLY-2608 for PIK3CA-mutant advanced solid tumors and breast cancer

This early study (Phase 1) tests RLY-2608, a targeted cancer drug for tumors with a PIK3CA mutation. It studies the drug alone and combined with hormone therapy (and sometimes CDK4/6 or CDK4 medicines) to see safety, dose, and whether it can shrink tumors.

Screening for financial hardship in advanced cancer

This study screens people with advanced cancer for financial problems. It aims to see if catching these problems early can improve your care and well-being.

STK-012 drug for advanced lung cancer and other tumors

This trial tests STK-012 (alone and with other treatments) in people with advanced cancers, especially non-small cell lung cancer. It may help by activating the immune system to recognize and fight the tumor.

Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer

GDC-1261 Safety and Activity in Advanced Prostate Cancer

This early-stage trial tests a new drug called GDC-1261 in men with advanced prostate cancer that has spread or gotten worse despite previous treatment. The study will look at whether the drug is safe and whether it helps slow or shrink the cancer.

Study tests a new prostate cancer drug after prior hormone therapy

This Phase 1 study tests the safety, how the drug moves through the body, and whether it shows anti-cancer activity in men with advanced or metastatic prostate cancer. It is designed for people whose cancer has already been treated with certain hormone (androgen receptor) therapies.

Study of ART0380 for advanced solid tumors

This study tests a new drug called ART0380 for people with advanced solid tumors that have not responded to standard treatments. It may be especially helpful for those with certain DNA repair gene changes (like ATM or BRCA). The drug will be given alone or with chemotherapy (gemcitabine or irinotecan) depending on the part of the trial.

New targeted therapy for BRCA/PALB2-mutated HR+ breast cancer

This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.

Combination therapy for advanced lung cancer

This trial tests a new combination of two investigational drugs, BNT324 and BNT327, for people with advanced lung cancer that cannot be removed by surgery. It aims to see if the combination is safe and effective for different types of lung cancer, including non-small cell and small cell lung cancer.

New Immunotherapy Drugs Before Surgery for Advanced Colorectal Cancer

This trial tests two immunotherapy drugs (botensilimab and balstilimab) given before surgery to treat advanced colorectal cancer that can be removed. The goal is to help the immune system fight cancer cells and improve outcomes after surgery.

Study drug for ER-positive, HER2-negative cancers after treatment

This Phase 2 study tests a new Pfizer medicine (PF-07248144) for certain advanced or metastatic breast, prostate, or lung cancers that have not responded to standard treatment or no standard options exist. You may qualify if you have a specific tumor type and a limited number of prior cancer treatments, and if your body functions (blood, liver, kidneys) and heart rhythm meet safety limits.

Comparing two drug combinations for advanced breast cancer

This trial tests two different combinations of medicines for people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has a specific gene change called PIK3CA. The goal is to see which combination is better at slowing down the cancer.

Testing a targeted pill for hard-to-treat solid tumors

This trial tests a new medicine (Q901) that targets a specific cell-control pathway to treat advanced cancers that have stopped responding to standard care. It’s mainly for people with certain solid tumor cancers, aiming to see whether the drug can shrink tumors or control disease.

Givastomig plus nivolumab and chemo for advanced stomach cancer

This trial tests a new drug, givastomig, combined with standard immunotherapy (nivolumab) and chemotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer. It is for people whose tumors have certain markers (CLDN18.2 and PD-L1) and who have not had treatment for advanced disease.

Study of KB707 for advanced cancers affecting the lungs

This trial tests a new medicine called KB707 for people with advanced cancers that affect the lungs. It uses a virus to deliver a gene that may help your immune system fight the tumor. The study is especially looking at people with lung cancer (NSCLC) or other solid tumors that have spread to the lungs and haven't responded to standard treatments.

Test drug OP-1250 with other medicines in ER-positive breast cancer

This Phase 1b study tests OP-1250 (palazestrant) combined with other targeted medicines for ER-positive, HER2-negative advanced or metastatic breast cancer. It mainly looks at safety and correct dosing, but may also help shrink tumors or slow growth.

FOG-001 for advanced solid tumors with certain gene changes

This trial tests a new drug, FOG-001, alone or with other treatments, for people with advanced solid tumors that have specific changes in the WNT pathway genes. It aims to see if the drug can shrink tumors or slow their growth.

Volrustomig for high-risk locally advanced cervical cancer

This trial tests a new medicine called volrustomig for women with locally advanced cervical cancer that has not spread. It is given along with standard chemoradiation and aims to improve outcomes.

Study of a new drug for advanced kidney cancer

This trial tests a new drug, PF-08634404, alone or with other cancer treatments, for adults with advanced kidney cancer that has not been treated before. It aims to see if the drug can help shrink tumors or stop them from growing.

Study of NXP900 for advanced solid tumors

This trial tests a new drug called NXP900 for people with advanced solid tumors that have not responded to other treatments. The study has two parts: one for any advanced solid tumor and another for tumors with specific genetic changes.

Virus therapy with chemo and immunotherapy for advanced lung cancer

This trial tests a new treatment that uses a virus to attack cancer cells, combined with standard chemotherapy and an immunotherapy drug, for people with advanced non-small cell lung cancer that has gotten worse after initial treatment. The goal is to see if this combination works better than a different chemotherapy drug alone.

Study of RAS inhibitors for advanced RAS-mutated lung cancer

This trial tests new drugs that target specific RAS mutations in advanced non-small cell lung cancer. It's for people whose cancer has a KRAS G12C, G12D, or other RAS mutation and who have already tried standard treatments.